NMBAs

PreclinicalSmall molecule

AAssistance Publique Hopitaux De Marseille

NMBAs is one of 4 small molecule programs targeting Trauma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TraumaRecruiting

TraumaPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Trauma

#DrugCompanyPhaseTrials

Sufenta

LLeaf Vertical Inc.

Phase 3

1 2

Penthrane

PPurdue Pharma, Canada

Preclinical

1 3

NMBAs

AAssistance Publique Hopitaux De Marseille

Preclinical

1 4

Hyperosmolar Sodium Lactate

IInnogene Kalbiotech Pte. Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Trauma

NCT06212492

Clinical

Trials by Indication[1]

Trauma1 trial

Effects on Biotrauma of NMBAs and PP Association During ARDS

Recruiting·AAssistance Publique Hopitaux De Marseille·N/A·NCT06212492·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NMBAs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NMBAs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NMBAs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique Hopitaux De Marseille company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAssistance Publique Hopitaux De Marseille

NMBAs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Trauma1 trial

References

Drug Info

Quick Facts

Related News